Drug Database
Back to search

Ireland· IE-PA-EU/1/25/2006/001

Aumseqa 55 mg film-coated tablets

A aumolertinib product containing aumolertinib mesilate, registered in Ireland by SFL Pharmaceuticals Deutschland GmbH. The same ATC class is registered in 8 of our 19 countries.

ATC L01EB11

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedAumseqa 55 mg film-coated tabletsATCL01EB11REGISTER NO.IE-PA-EU/1/25/2006/001PACKS LISTED1CHECKEDSeptember 28, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about aumolertinib mesilateAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Aumolertinib is registered in 8 of 19 countries.

Countries holding a registration under ATC L01EB11 (aumolertinib), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 5 of them publish a price we can compare per daily dose
Search aumolertinib products by name

Aumolertinib · ATC L01EB11

8 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

HPRA (Ireland)
Active substance
Aumolertinib mesilate
Manufacturer
SFL Pharmaceuticals Deutschland GmbH
Country
Ireland (IE)
ATC code
L01EB11
ATC class
Aumolertinib
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/25/2006/001

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Aumolertinib in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All aumolertinib products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/fb3a5ca0-d414-4cec-a24e-3420f9ce6c42
GET /v1/drugs/fb3a5ca0-d414-4cec-a24e-3420f9ce6c42?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "routes": [
    "Oral use"
  ],
  "source": "hpra",
  "atc_all": [
    "L01EB11"
  ],
  "strength": null,
  "pa_number": "EU/1/25/2006/001",
  "substances": [
    "Aumolertinib mesilate"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": "12/02/2026",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}
API referenceMCP serverPlans

See everything about aumolertinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console